• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    1/9/24 4:30:00 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023.

    Third Quarter Fiscal Year 2024 Financial Overview   

    • Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.
    • Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.
    • S&SS revenue was $34.5 million, representing a 15% decline QoQ and a 30% decline YoY. 
    • Telematics Products revenue was $19.2 million, representing a 10% decline QoQ and a 35% decline YoY. 
    • Recurring Application Subscription revenues were $17.8 million in the quarter, representing a 5% decline QoQ as well as YoY.  
    • Adjusted EBITDA was $1.0 million, representing a $4.8 million decline QoQ and a $3.7 million decline YoY.  
    • GAAP net loss from continuing operations was $85 million, or a loss of $2.27 per share.  This includes the impact of a $74 million goodwill impairment charge. 
    • Ended the quarter with $38.2 million in cash and cash equivalents down $400K QoQ. 

    "In the third quarter, strength in our industrial and connected car segments was offset by soft demand in our TSP segment.  Soft demand with TSPs led to lower than expected consolidated revenue and Adjusted EBITDA.  We continue to work closely with our TSP customers as they rebalance inventory levels and respond to an overall competitive environment.  We are optimistic that our rejuvenated efforts in this segment will result in a return to revenue growth from current levels" said Interim CEO, Jason Cohenour. "During the quarter, we also implemented initiatives to narrow our strategic focus and to reduce cash expenses by approximately $16 million on an annualized basis.  Our sharpened focus on core segments, combined with a more efficient cost structure, adds considerable leverage to our operating model as we strive for a return to profitable growth." 

    Business and Recent Highlights  

    • Announced on January 8, 2024, the appointment of veteran technology leader Chris Adams as President and Chief Executive Officer, effective January 22, 2024.
    • Announced on December 18, 2023, the closing of a $45 million term loan with Lynrock Lake Master Fund LP to provide the company with additional financial capacity in support of its business transformation. 
    • CalAmp's international connected car solution was granted Toyota "Genuine" status, enabling port installation, and streamlining the sales and customer delivery process.
    • Released the new Vision 2.1 solution, enabling telematics functionality through the standalone dash cam. 
    • Completed the technical migration of devices from legacy PULS device management platform to DMCTC.

    Summary Financial Information From Continuing Operations:

    (In thousands except per share amounts)

      Three Months Ended  Nine Months Ended 
      November 30,  November 30, 
    Description 2023  2022  2023  2022 
    Revenues:            
    Software & Subscription Services (S&SS) $34,456  $49,264  $119,766  $133,332 
    Telematics Products  19,169   29,625   66,464   83,111 
      $53,625  $78,889  $186,230  $216,443 
                 
    Gross margin  33%  34%  36%  38%
                 
    Net loss $(85,004) $(4,733) $(93,261) $(24,400)
    Net loss per diluted share $(2.27) $(0.13) $(2.52) $(0.68)
    Non-GAAP measures:            
    Adjusted EBITDA $1,031  $4,698  $12,950  $11,320 
    Adjusted EBITDA margin  2%  6%  7%  5%
                 
                 
    Cash Flow from Operations $1,830  $3,834  $5,993  $(21,841)



      November 30,  February 28, 
    Description 2023  2023 
    Cash and cash equivalents $38,169  $41,928 
    Working capital  69,258   68,295 
    Deferred revenue  37,434   36,552 
    Total debt (carrying value)  228,148   228,121 
           



      November 30, 
    S&SS Supplemental Information: 2023  2022 
    Remaining performance obligations $186,036  $252,200 
    Subscribers  1,833   1,460 



     Three Months Ended 
     Nov 30, 2023  Nov 30, 2022  Aug 31, 2023 
    Revenue by type of goods and services:        
    Telematics devices and accessories (1)$31,217  $53,331  $37,358 
    Rental income and other services$4,583   6,307  $5,656 
    Recurring application subscriptions (2)$17,825   19,251  $18,700 
    Total$53,625  $78,889  $61,714 
             
    Recurring application subscriptions, excluding Automotive Vehicle Finance Business (1)$17,823  $18,761  $18,694 

    (1) Telematics devices and accessories during the three months ended August 31, 2023 includes a reversal of $1.2M of revenue related to an exchange of product in support of our customer's specialized regional requirements.

    (2) Recurring application subscriptions includes $0.0 million, $0.5 million, and $0.0 million during the three months ended November 30, 2023, November 30, 2022, and August 31, 2023, respectively, attributable to the auto vehicle finance business which has been completely wound down. The three months ended August 31, 2023 additionally includes ($0.4M) of adjustments related to prior periods.

    Fourth Quarter Fiscal Year 2024 Business Outlook

    We expect Q4 FY24 revenues to be down slightly on a sequential basis and adjusted EBITDA to be stable.

    A reconciliation of non-GAAP guidance financial measures to corresponding GAAP guidance financial measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty and potential variability of expenses, such as stock-based compensation expense-related charges, that may be incurred in the future and cannot be reasonably determined or predicted at this time. It is important to note that these factors could be material to our results of operations computed in accordance with GAAP.

    Conference Call and Webcast

    CalAmp is hosting a conference call for analysts and investors to discuss its third quarter fiscal year 2024 results at 2:00 p.m. Pacific Time today. Participants can listen in via webcast by visiting the Investor Relations section of its website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available for 90 days after the call. The conference call can also be accessed by dialing 833-470-1428 (+1-404-975-4839 for international callers) and using the Conference ID #757030. Following the call, an audio replay will also be available by calling 866-813-9403 or 1-929-458-6194 and entering the Replay ID # 181919. The audio replay will be available through January 16, 2024.

    About CalAmp

    CalAmp (NASDAQ:CAMP) provides flexible solutions to help organizations worldwide monitor, track and protect their vital assets. Our unique combination of software, devices, and platform enables commercial and government organizations worldwide to increase efficiency, safety and transparency while accommodating the unique ways they do business. With over 10 million active edge devices and 275+ issued or pending patents, CalAmp is the telematics leader organizations turn to for innovation and dependability. For more information, visit calamp.com, or LinkedIn, Twitter, YouTube or CalAmp Blog.

    Forward-Looking Statements

    This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning CalAmp. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, (ii) our competitive position and opportunities, (iii) our comprehensive review of strategic alternatives focused on enhancing shareholder value, and (iv) other statements identified by words such as such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict", "project", "aim", "goal", and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, current market trends and market conditions, and involve risks and uncertainties, many of which are outside of our control, and which may cause actual results to differ materially from those contained in forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect future results include any risks associated with global economic conditions and concerns; the outcome of our comprehensive review of strategic alternatives, including the availability of any strategic alternatives that are worthwhile to pursue; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic; global component shortages due to supply chain constraints caused by the COVID-19 pandemic; disruptions in sales, operations, relationships with customers, suppliers, employees; our ability to successfully and timely accomplish our transformation to a SaaS solutions provider; our transition out of the automotive vehicle financing business; competitive pressures; pricing declines; demand for our telematics products; rates of growth in our target markets; prolonged disruptions of our contract manufacturers' facilities or other significant operations; force majeure or force-majeure-like events at our contract manufacturers' facilities including component shortages; the ongoing diversification of our global supply chain; our dependence on outsourced service providers for certain key business services and their ability to execute to our requirements; our ability to improve gross margin; cost-containment measures; legislative, trade, tariff, and regulatory actions; integration, unexpected charges or expenses in connection with acquisitions; the impact of legal proceedings and compliance risks; the impact on our business and reputation from information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data protection; our ability to protect our intellectual property and the unpredictability of any associated litigation expenses; any expenses or reputational damage associated with resolving customer product and warranty and indemnification claims; our ability to sell to new types of customers and to keep pace with technological advances; market acceptance of the end products into which our products are designed; and other events and trends on a national, regional and global scale, including those of a political, economic, business, competitive, and regulatory nature. More information on these risks and other potential factors that could affect our financial results is included in our filings with the U.S. Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings, which you may obtain for free at the SEC's website at http://www.sec.gov. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, which speak as of their respective dates except as required by law.

    Non-GAAP Financial Measures

    "GAAP" refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the SEC. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. These non-GAAP financial measures are provided in addition to, and not as a substitute for measures of financial performance prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation, acquisition and integration expenses, non-cash costs and expenses arising from purchase accounting adjustments, litigation and legal expenses, impairment losses and certain other adjustments as detailed in the accompanying non-GAAP reconciliation), and Adjusted EBITDA margin. We use these non-GAAP financial measures to provide investors with additional information about our financial performance and future prospects of our core business activities. Internally, these non-GAAP measures are significant measures used by management for purposes of evaluating our core operating performance, establishing internal budgets, calculating return on investment for development programs and growth initiatives, comparing performance with internal forecasts and targeted business models, strategic planning, evaluating and valuing potential acquisition candidates and how their operations compare to our operations, and benchmarking performance externally against our competitors. We believe this non-GAAP financial information provides additional insight into our ongoing performance and have therefore chosen to provide this information to investors to help them evaluate our results of ongoing operations and enable additional period-to-period comparisons. The presentation of these and other similar items in our non-GAAP financial results should not be interpreted as implying that these items are non-recurring, infrequent, or unusual.

    CalAmp, LoJack, TRACKER, Here Comes The Bus, Bus Guardian, iOn Vision, CrashBoxx and associated logos are among the trademarks of CalAmp and/or its affiliates in the United States, certain other countries and/or the EU. Spireon acquired the LoJack® U.S. Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada. Any other trademarks or trade names mentioned are the property of their respective owners.

    AT CALAMP:CalAmp Media
    Jikun KimContact:
    SVP & CFOMark Gaydos
    [email protected] Chief Marketing & Product Officer
     [email protected] 



    CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands, except per share amounts)

    (Unaudited)
     
      
     Three Months Ended  Fiscal Year Ended 
     November 30,  November 30, 
      2023   2022   2023   2022 
                    
    Revenues$53,625  $78,889  $186,230  $216,443 
    Cost of revenues 36,051  $52,275   119,251   135,170 
    Gross profit 17,574   26,614   66,979   81,273 
    Operating expenses:               
    Research and development 4,051  $5,479   14,693   19,236 
    Selling and marketing 8,884  $12,486   29,525   36,698 
    General and administrative 10,114  $11,172   31,482   39,864 
    Intangible asset amortization 1,116  $1,323   3,466   3,995 
    Restructuring 1,718  $-   1,718   - 
    Impairment loss 75,106   -   75,106   - 
    Total operating expenses 100,989   30,460   155,990   99,793 
    Operating loss (83,415)  (3,846)  (89,011)  (18,520)
    Non-operating income (expense):               
    Investment income (124) $818   360   646 
    Interest expense (1,410) $(1,648)  (4,662)  (4,645)
    Other expense, net (17) $211   577   (1,238)
    Total non-operating expenses (1,551)  (619)  (3,725)  (5,237)
    Loss from operations before income taxes (84,966)  (4,465)  (92,736)  (23,757)
    Income tax provision (38) $(268)  (525)  (643)
    Net loss$(85,004) $(4,733) $(93,261) $(24,400)
    Loss per share - continuing operations:               
    Basic$(2.27) $(0.13) $(2.52) $(0.68)
    Diluted$(2.27) $(0.13) $(2.52) $(0.68)
    Shares used in computing earnings (loss) per share:               
    Basic 37,427   36,357   37,023   36,027 
    Diluted 37,427   36,357   37,023   36,027 



    CALAMP CORP.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)
     
      
        November 30,  February 28, 
        2023  2023 
    Assets         
               
    Current assets:          
    Cash and cash equivalents   $38,169  $41,928 
    Accounts receivable, net    70,909   82,946 
    Inventories    34,059   23,902 
    Prepaid expenses and other current assets    25,824   26,019 
    Total current assets    168,961   174,795 
               
    Property and equipment, net    25,724   32,832 
    Operating lease right-of-use assets    10,168   12,293 
    Deferred income tax assets    2,927   3,275 
    Goodwill    20,583   94,214 
    Other intangible assets, net    23,608   26,633 
    Other assets    29,270   36,078 
    Total assets   $281,241  $380,120 
               
    Liabilities and Stockholders' Equity          
               
    Current liabilities:          
    Current portion of long-term debt   $-  $705 
    Accounts payable    46,695   52,716 
    Accrued payroll and employee benefits    10,112   11,766 
    Deferred revenue    26,328   25,448 
    Other current liabilities    16,568   15,865 
    Total current liabilities    99,703   106,500 
               
    Long-term debt, net of current portion    228,148   227,416 
    Operating lease liabilities    9,007   12,314 
    Other non-current liabilities    18,522   19,583 
    Total liabilities    355,380   365,813 
    Stockholders' equity:          
    Common stock    379   374 
    Additional paid-in capital    189,747   184,672 
    Accumulated deficit    (262,077)  (168,816)
    Accumulated other comprehensive loss    (2,188)  (1,923)
    Total stockholders' equity    (74,139)  14,307 
    Total liabilities and stockholders' equity   $281,241  $380,120 
               



     CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)
     
       
      Nine Months Ended 
      November 30, 
       2023   2022 
    CASH FLOWS FROM OPERATING ACTIVITIES:       
     Net loss$(93,261) $(24,400)
             
     Depreciation expense 12,632   12,108 
     Intangible asset amortization 3,466   3,995 
     Stock-based compensation 5,469   8,186 
     Amortization of debt issuance costs and discount 825   877 
     Impairment losses 75,106   - 
     Non-cash operating lease cost 2,575   2,591 
     Revenue assigned to factors (798)  (2,143)
     Deferred tax assets, net 480   132 
     Other 381   122 
     Changes in operating assets and liabilities of continuing operations (882)  (23,309)
    NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 5,993   (21,841)
             
    CASH FLOWS FROM INVESTING ACTIVITIES:       
     Capital expenditures (6,176)  (9,294)
    NET CASH USED IN INVESTING ACTIVITIES (6,176)  (9,294)
             
    CASH FLOWS FROM FINANCING ACTIVITIES:       
     Taxes paid related to net share settlement of vested equity awards (520)  (1,675)
     Proceeds from exercise of stock options and contributions to employee stock purchase plan 131   502 
    NET CASH USED IN FINANCING ACTIVITIES (389)  (1,173)
             
    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (3,187)  (2,007)
    Net change in cash and cash equivalents (3,759)  (34,315)
    Cash and cash equivalents at beginning of period 41,928   79,221 
    Cash and cash equivalents at end of period$38,169  $44,906 

    CALAMP CORP.

    RECONCILIATION OF NON-GAAP MEASURES TO GAAP

    (Unaudited)

    GAAP refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. The presentation of non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation and other adjustments as identified below), and Adjusted EBITDA margin. We use these non-GAAP financial measures to provide investors with an overall understanding of the financial performance and future prospects of our core business activities. Specifically, we believe that the use of these non-GAAP measures facilitates the comparison of results of core business operations between current and past periods.

    The reconciliation of GAAP-basis net loss to Adjusted EBITDA and the calculation of Adjusted EBITDA margin are as follows (dollars in thousands):

     Three Months Ended  Nine Months Ended 
     November 30,  November 30, 
     2023  2022  2023  2022 
                    
    GAAP basis net loss$(85,004) $(4,733) $(93,261) $(24,400)
                    
    Investment (income) loss 124   (818)  (360)  (646)
    Interest expense 1,410   1,648   4,662   4,645 
    Income tax provision 38   268   525   643 
    Depreciation and amortization 4,953   5,216   16,098   16,103 
    Stock-based compensation 1,567   2,030   5,469   8,186 
    Litigation and non-recurring legal expenses 91   86   280   4,634 
    Restructuring 1,718   -   1,718   - 
    Costs incurred in transition of LoJack North America business to acquiror (a) (79)  232   (319)  1,217 
    Impairment loss 75,106   -   75,106   - 
    Other 1,107   769   3,032   938 
    Adjusted EBITDA$1,031  $4,698  $12,950  $11,320 
                    
    Revenues$53,625  $78,889  $186,230  $216,443 
                    
    Adjusted EBITDA margin 2%  6%  7%  5%

    (a) Costs incurred in transition of business to acquiror are attributable to the wind-down and transfer of the LoJack North America business to Spireon.



    Primary Logo

    Get the next $CAMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    12/22/2021$14.00 → $10.00Buy → Hold
    Craig-Hallum
    9/24/2021$16.00 → $14.00Buy
    Craig Hallum
    6/25/2021$19.00 → $18.50Buy
    Roth Capital
    More analyst ratings

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP
    • CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three

      4/28/25 4:30:00 PM ET
      $CAMP
    • CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics de

      3/27/25 4:05:00 PM ET
      $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP
    • Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 5:05:20 PM ET
      $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    See more
    • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

      IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

      1/9/24 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

      IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

      12/26/23 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

      IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

      12/18/23 4:31:00 PM ET
      $CAMP

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP
    • JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

      JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

      11/5/24 6:14:20 AM ET
      $CAMP

    $CAMP
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP
    • SEC Form 10-Q filed by CAMP4 Therapeutics Corporation

      10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:26:54 PM ET
      $CAMP
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:20:45 PM ET
      $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    See more
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalAmp Appoints Chris Adams as President and Chief Executive Officer

      IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

      1/8/24 6:30:00 AM ET
      $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Bumcrot David

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:09:40 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Medical Officer Maricich Yuri

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:08:11 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Financial Officer Gold Kelly

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:07:07 PM ET
      $CAMP